Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today said that the U.S. Food and Drug Administration (FDA) has
requested the submission of new data and analyses from the MODIFY I and
MODIFY II clinical trials previously submitted to the pending Biologics
Licensing Application (BLA) for bezlotoxumab, an investigational agent
for prevention of < i > Clostridium difficile < /i > ( < i > C. difficile < /i > )
infection recurrence. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div class= " field-item odd " >
English < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-contact-html field-fieldpressreleasecontacthtml " > < div class= " field-label " > Contact: < /div > < div class= " field-items " > < div class= " field-item odd " > < p > Merck < br / > Media: < br / > Pamela Eisele, 267-305-3558 < br / > Rober...

Source: Merck.com - Corporate News - July 21, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Bezlotoxumab MSD NYSE:MRK Source Type: news